On its way to mak­ing Hong Kong his­to­ry, As­cle­tis eyes $457M haul in GIC-backed IPO

7 years ago
Financing
China

Vivek Ra­maswamy strikes again, this time launch­ing a Bei­jing-based biotech play­er with a pipeline

7 years ago
Startups

The next Nim­bus? Head of bil­lion-dol­lar drug pro­gram launch­es HotSpot with $45M A round

7 years ago
Financing
Startups

Fast-grow­ing As­cen­t­age has big plans for its lat­est $150M raise -- but what about the IPO?

7 years ago
Financing
China

Roche hands over an­oth­er batch of pos­i­tive PhI­II da­ta on its new flu drug, look­ing for an ear­ly-win­ter launch

7 years ago
R&D

J&J de­clares a his­toric suc­cess as In­vokana comes through in PhI­II chron­ic kid­ney dis­ease tri­al

7 years ago
R&D

An­oth­er stark warn­ing over CRISPR/Cas9’s po­ten­tial to do last­ing harm dents share prices

7 years ago
Pharma

FDA ex­perts back GSK's new malar­ia drug; Sang­amo's new­ly mint­ed CTO jumps to biotech up­start

7 years ago
News Briefing

Phar­ma 'greed' emerges as a po­tent po­lit­i­cal is­sue in a rau­cous elec­tion year

7 years ago
Pharma

Tak­ing on biode­fense threats, an­tibi­otics mak­er Spero inks $54M in gov­ern­ment deals

7 years ago
R&D
Pharma

Chas­ing Bio­gen, the Pli­ant crew banks a $62M round to fu­el their shot at fi­bro­sis tar­gets

7 years ago
Financing

Guard­ing against a night­mare sce­nario, FDA ap­proves new drug to counter small­pox out­break

7 years ago
Pharma

Back­ers of Tes­la and SpaceX fund 29-year-old Al­ice Zhang's AI-pow­ered neu­ro­science start­up

7 years ago
Financing
Startups

A uni­corn joins this week’s stam­pede of biotechs in­to the red-hot Nas­daq casi­no

7 years ago
Financing

Vant com­man­der Ra­maswamy heads back to Nas­daq with a $150M pitch — are in­vestors ready to for­give Ax­o­vant?

7 years ago
Financing

Tai­ho kicks off $130M Ar­cus deal with drug op­tion; J&J al­lies with Mer­ck KGaA to take di­a­betes drug to Chi­na

7 years ago
News Briefing

George Golumbeski's first stop out of Cel­gene: Grail; Roivant taps Genen­tech vet Myr­tle Pot­ter for op­er­a­tions role

7 years ago
Peer Review

Af­ter long de­lay fol­low­ing pa­tient death, FDA lifts tri­al hold on Ad­vax­is/As­traZeneca com­bo

7 years ago
Pharma

Sen­ate Dems blast No­var­tis’ ties to Trump at­tor­ney, claim phar­ma gi­ant of­fered mis­lead­ing ex­pla­na­tions in damn­ing ...

7 years ago
Pharma

Bio­gen vet George Scan­gos jumps on the board at up­start MS case man­ag­er Oc­tave, backed by Sec­tion 32

7 years ago
People
Financing

Am­gen, UCB are back pitch­ing once-re­ject­ed os­teo­poro­sis drug ro­mo to the FDA — but big hur­dles lie ahead

7 years ago
Pharma

In­ves­tiga­tive re­port calls for re­newed scruti­ny on Aca­dia drug; Im­bru­vi­ca fails in front­line DL­B­CL PhI­II

7 years ago
News Briefing

On the heels of GW's epilep­sy win, Wall Street dar­ling Zo­genix shares pos­i­tive PhI­II da­ta on ri­val drug

7 years ago
R&D

Hop­ing to shake Al­ler­gan/Shire's dry eye dom­i­nance, Oys­ter Point posts pos­i­tive Phase IIb da­ta for ri­val drug

7 years ago
R&D
First page Previous page 1012101310141015101610171018 Next page Last page
A service from the Financial Times